Lung Cancer | Specialty

FDA Approvals for Daratumumab and Osimertinib, Regulatory Advances in RCC and CLL, and More

November 21st 2015

FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC

November 16th 2015

The FDA has requested additional clinical trial data to support a new drug application for rociletinib as a potential therapy for pretreated patients with EGFR T790M mutation-positive NSCLC.

FDA Approves Osimertinib for EGFR T790M-Positive NSCLC

November 13th 2015

The FDA has granted an accelerated approval to osimertinib for patients with advanced EGFR T790M mutation positive non–small cell lung cancer following prior therapy on a prior EGFR TKI.

Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung Cancer

November 12th 2015

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

November 9th 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

PD-1 Agents Top Choice for Second-Line NSCLC

November 9th 2015

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Dr. Levy on EGFR TKIs in Lung Cancer

November 9th 2015

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Nivolumab Demonstrates Broad Efficacy in NSCLC

November 7th 2015

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Targeting Rare Mutations in NSCLC the Way of the Future

November 7th 2015

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Checkpoint Inhibitors Show Promise in SCLC, Mesothelioma

November 7th 2015

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Marianne Davies on Managing Immunotherapy Side Effects in Lung Cancer

November 2nd 2015

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

Dr. Minna on Chemotherapy and Radiation Therapy for Lung Cancer

November 2nd 2015

John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.

Biomarkers Take Center Stage in Lung Cancer

November 1st 2015

Clinical trial designs are transforming dramatically in order to expedite the discovery and validation of new predictive biomarkers for patients with non–small cell lung cancer and other types of solid tumors.

Expert Discusses Future of Immunotherapy in Lung Cancer

October 30th 2015

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

Debating the Merits of New Therapeutic Stars in NSCLC

October 29th 2015

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

Marking Bunn's Lifetime of Leadership in Lung Cancer Care

October 29th 2015

The impact upon cancer care, made by Paul Bunn, MD, extends far beyond the programs he helped build in Colorado.

Pembrolizumab Improves Survival Versus Docetaxel in PD-L1+ NSCLC

October 26th 2015

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

October 23rd 2015

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.

Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More

October 16th 2015

Nivolumab Investigator Discusses Expanded Approval, Compares With Pembrolizumab

October 16th 2015

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.